Interleukin (IL)-6 is a pleiotropic cytokine that has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro. In patients with metastasizing melanomas, highly increased IL-6 blood levels correlate with a poor response to chemotherapy and a worse overall prognosis, suggesting that IL-6 promotes melanoma progression in vivo. Here, we analyzed the role of IL-6 in melanoma development and progression in a transgenic mouse model. We bred IL-6-deficient mice with MT-ret transgenic animals predisposed for melanomas. While MT-ret transgenic animals develop severe melanosis of the skin and subcutis and subsequent melanomas at an incidence of 80% during their first year of life, MT-ret mice devoid of IL-6 developed preneoplastic melanosis and consecutive melanomas significantly less frequently (47%; P < 0.05). Moreover, the tumors were significantly smaller in the groups of MT-ret mice lacking one (P < 0.05) or both (P < 0.01) copies of the IL-6 gene. Immunoblot analysis revealed that ret transgene expression was not reduced in the skin of mice lacking IL-6, indicating that the observed decrease of melanoma incidence and of tumor sizes was not because of a down-regulation of transgene expression. Interleukin (IL)-6 is a pleiotropic cytokine that induces the acute phase response, stimulates B-and T-lymphocytes, and regulates the growth, differentiation, and death of several cell populations including neurons and melanocytes. 1-3 IL-6 promotes the development and progression of plasmacytomas 4 and gliomas 4,5 in vivo. It is also a growth-promoting factor for human basal cell carcinoma, Kaposi's sarcoma, and prostate cancer cells in vitro. 3,6 The IL-6 receptor system consists of IL-6 receptor ⣠(IL-6RâŁ), the primary IL-6 receptor, and the ubiquitous gp130 signal-transducing receptor subunit. Binding of IL-6 to its receptor complex leads to the activation of janus kinases (Jaks) and subsequent phosphorylation, dimerization, and nuclear translocation of signal transducer and activator of transcription 3 (STAT3). 2,7 STAT3 promotes tumor progression by regulating the expression of genes involved in growth control such as c-myc, antiapoptosis [Bcl-x(L) and Mcl-1] and angiogenesis (vascular endothelial growth factor). 8 -11 In a recent study, STAT3 was found to be constitutively activated in some, but not all human melanoma cell lines and tumor specimens analyzed. 12 However, blocking experiments revealed that STAT3 activation in these cell lines was apparently mainly caused by Src tyrosine kinase activity and not by Jak activation. 12